Regional Anesthesia and Anticoagulation

Chapter

Key Points

  • Bleeding complications following regional anesthesia are an uncommon but real concern, and are dependent on patient- and procedure-specific factors.

  • A thorough patient history is necessary to identify any preexisting coagulopathy, use of anticoagulants or other agents which may exacerbate bleeding concomitant with regional anesthesia procedures.

  • It is expected that regional anesthesiologists will increasingly encounter patients treated with popular anticoagulant drugs, including NSAIDs, warfarin, heparin, and ADP receptor blockers, as well as newer anticoagulants and other agents affecting coagulation (e.g., SSRIs/SNRIs), as more elderly individuals undergo surgery.

  • Not only do we need to be very knowledgeable about newer developments in the ever changing world of anticoagulation, we also need to temper our enthusiasm for performing invasive procedures on patients who are at high risk for bleeding complications.

Keywords

Anticoagulation NSAIDs Aspirin Warfarin Heparin Clopidogrel Prasugrel Rivaroxaban Dabigatran Herbal anticoagulants 

Abbreviations

ASRA

American Society of Regional Anesthesia and Pain Medicine

INR

International normalized ratio

PT

Prothrombin time

PTT

Partial thromboplastin time

SNRI

Serotonin norepinephrine reuptake inhibitors

SSRI

Selective serotonin reuptake inhibitors

References

  1. 1.
    Auroy Y, Benhamou D, Bargues L, Ecoffey C, Falissard B, Mercier FJ, Bouaziz H, Samii K. Major complications of regional anesthesia in France: the SOS Regional Anesthesia Hotline Service. Anesthesiology. 2002;97:1274–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, Mulroy MF, Rosenquist RW, Rowlingson J, Tryba M, Yuan CS. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med. 2003;28:172–97.PubMedGoogle Scholar
  3. 3.
    Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990–1999. Anesthesiology. 2004;101:950–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Breivik H, Bang U, Jalonen J, Vigfusson G, Alahuhta S, Lagerkranser M. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand. 2010;54:16–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Gogarten W, Vandermeulen E, Van AH, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015.CrossRefPubMedGoogle Scholar
  6. 6.
    Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, Brown DL, Heit JA, Mulroy MF, Rosenquist RW, Tryba M, Yuan CS. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010;35:64–101.CrossRefPubMedGoogle Scholar
  7. 7.
    Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De AJ, Deer TR, Rauck R, Huntoon MA. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40:182–212.CrossRefPubMedGoogle Scholar
  8. 8.
    Igarashi T, Hirabayashi Y, Shimizu R, Saitoh K, Fukuda H, Mitsuhata H. The lumbar extradural structure changes with increasing age. Br J Anaesth. 1997;78:149–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Ekatodramis G, Macaire P, Borgeat A. Prolonged Horner syndrome due to neck hematoma after continuous interscalene block. Anesthesiology. 2001;95:801–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Ben-David B, Stahl S. Axillary block complicated by hematoma and radial nerve injury. Reg Anesth Pain Med. 1999;24:264–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Bergman BD, Hebl JR, Kent J, Horlocker TT: Neurologic complications of 405 consecutive continuous axillary catheters. Anesth Analg 2003; 96: 247–252, tableGoogle Scholar
  12. 12.
    Cockings E. Axillary block complicated by hematoma and radial nerve injury. Reg Anesth Pain Med. 2000;25:103.CrossRefPubMedGoogle Scholar
  13. 13.
    Tsao BE, Wilbourn AJ. Infraclavicular brachial plexus injury following axillary regional block. Muscle Nerve. 2004;30:44–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Aida S, Takahashi H, Shimoji K. Renal subcapsular hematoma after lumbar plexus block. Anesthesiology. 1996;84:452–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Aveline C, Bonnet F. Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J Anaesth. 2004;93:589–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Hsu DT. Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J Anaesth. 2005;94:395–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Klein SM, D’Ercole F, Greengrass RA, Warner DS. Enoxaparin associated with psoas hematoma and lumbar plexopathy after lumbar plexus block. Anesthesiology. 1997;87:1576–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Weller RS, Gerancher JC, Crews JC, Wade KL. Extensive retroperitoneal hematoma without neurologic deficit in two patients who underwent lumbar plexus block and were later anticoagulated. Anesthesiology. 2003;98:581–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Nielsen CH. Bleeding after intercostal nerve block in a patient anticoagulated with heparin. Anesthesiology. 1989;71:162–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Najean Y, Ardaillou N, Dresch C. Platelet lifespan. Annu Rev Med. 1969;20:47–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–64S.CrossRefPubMedGoogle Scholar
  23. 23.
    Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Lotrionte M, Biondi-Zoccai GG. The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease. Curr Opin Cardiol. 2008;23:487–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Oscarsson A, Gupta A, Fredrikson M, Jarhult J, Nystrom M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104:305–12.CrossRefPubMedGoogle Scholar
  26. 26.
    Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med. 2005;257:399–414.CrossRefPubMedGoogle Scholar
  27. 27.
    Buvanendran A, Young AC. Spinal epidural hematoma after spinal cord stimulator trial lead placement in a patient taking aspirin. Reg Anesth Pain Med. 2014;39:70–2.CrossRefPubMedGoogle Scholar
  28. 28.
    Giberson CE, Barbosa J, Brooks ES, McGlothlen GL, Grigsby EJ, Kohut JJ, Wolbers LL, Poree LR. Epidural hematomas after removal of percutaneous spinal cord stimulator trial leads: two case reports. Reg Anesth Pain Med. 2014;39:73–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Pryle BJ, Carter JA, Cadoux-Hudson T. Delayed paraplegia following spinal anaesthesia. Spinal subdural haematoma following dural puncture with a 25 G pencil point needle at T12-L1 in a patient taking aspirin. Anaesthesia. 1996;51:263–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Seow K, Drummond KJ. Subdural spinal haematoma after spinal anaesthesia in a patient taking aspirin. J Clin Neurosci. 2011;18:1713–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Panara MR, Renda G, Sciulli MG, Santini G, Di GM, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999;290:276–80.PubMedGoogle Scholar
  32. 32.
    Hegi TR, Bombeli T, Seifert B, Baumann PC, Haller U, Zalunardo MP, Pasch T, Spahn DR. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. Br J Anaesth. 2004;92:523–31.CrossRefPubMedGoogle Scholar
  33. 33.
    Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Meunier A, Lisander B, Good L. Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Acta Orthop. 2007;78:661–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591–602.CrossRefPubMedGoogle Scholar
  36. 36.
    Benzon HT, Avram MJ, Benzon HA, Kirby-Nolan M, Nader A. Factor VII levels and international normalized ratios in the early phase of warfarin therapy. Anesthesiology. 2010;112:298–304.CrossRefPubMedGoogle Scholar
  37. 37.
    Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing–recalibrating expectations. N Engl J Med. 2013;369:2273–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049–56.CrossRefPubMedGoogle Scholar
  39. 39.
    Woolson ST, Zehnder JL, Maloney WJ. Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty. J Arthroplasty. 1998;13:207–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Ahmed I, Gertner E. Safety of arthrocentesis and joint injection in patients receiving anticoagulation at therapeutic levels. Am J Med. 2012;125:265–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Conway R, O’Shea FD, Cunnane G, Doran MF. Safety of joint and soft tissue injections in patients on warfarin anticoagulation. Clin Rheumatol. 2013;32:1811–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Ruff RL, Dougherty Jr JH. Complications of lumbar puncture followed by anticoagulation. Stroke. 1981;12:879–81.CrossRefPubMedGoogle Scholar
  43. 43.
    Liu SS, Mulroy MF. Neuraxial anesthesia and analgesia in the presence of standard heparin. Reg Anesth Pain Med. 1998;23:157–63.CrossRefPubMedGoogle Scholar
  44. 44.
    Haldar S, Hudsmith L, Munir S. Cervical extradural haematoma following thrombolysis. Heart. 2005;91:422.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Greaves JD. Serious spinal cord injury due to haematomyelia caused by spinal anaesthesia in a patient treated with low-dose heparin. Anaesthesia. 1997;52:150–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Sandhu H, Morley-Forster P, Spadafora S. Epidural hematoma following epidural analgesia in a patient receiving unfractionated heparin for thromboprophylaxis. Reg Anesth Pain Med. 2000;25:72–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med. 1998;23:164–77.PubMedGoogle Scholar
  48. 48.
    U.S. Food and Drug Administration. Updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins. 1-19-2016. U.S. Department of Health & Human Services.Google Scholar
  49. 49.
    Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–24.CrossRefPubMedGoogle Scholar
  51. 51.
    Breuer G, Weiss DR, Ringwald J. ‘New’ direct oral anticoagulants in the perioperative setting. Curr Opin Anaesthesiol. 2014;27:409–19.CrossRefPubMedGoogle Scholar
  52. 52.
    Levy S. Newer clinically available antithrombotics and their antidotes. J Interv Card Electrophysiol. 2014;40:269–75.CrossRefPubMedGoogle Scholar
  53. 53.
    Connolly G, Spyropoulos AC. Practical issues, limitations, and periprocedural management of the NOAC’s. J Thromb Thrombolysis. 2013;36:212–22.CrossRefPubMedGoogle Scholar
  54. 54.
    Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med. 2013;8:477–84.CrossRefPubMedGoogle Scholar
  55. 55.
    Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, LaCreta F. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776–86.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75:476–87.CrossRefPubMedGoogle Scholar
  57. 57.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMedGoogle Scholar
  58. 58.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMedGoogle Scholar
  59. 59.
    Ericksson, BI., Dahl, OE, Buller, HR. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3, 103–111.Google Scholar
  60. 60.
    Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009;101:77–85.PubMedGoogle Scholar
  61. 61.
    Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van RJ. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47–59.CrossRefPubMedGoogle Scholar
  63. 63.
    Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11:245–52.CrossRefPubMedGoogle Scholar
  64. 64.
    Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69:1473–84.CrossRefPubMedGoogle Scholar
  65. 65.
    Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis. 2013;35:391–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Schiele F, van RJ, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.CrossRefPubMedGoogle Scholar
  67. 67.
    Ericksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1–22.CrossRefGoogle Scholar
  68. 68.
    Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–80.CrossRefPubMedGoogle Scholar
  69. 69.
    Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24:2757–65.CrossRefPubMedGoogle Scholar
  70. 70.
    Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost. 2007;33:515–23.CrossRefPubMedGoogle Scholar
  71. 71.
    Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.CrossRefPubMedGoogle Scholar
  72. 72.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMedGoogle Scholar
  73. 73.
    de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106–9.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164:2367–70.CrossRefPubMedGoogle Scholar
  75. 75.
    Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. Encephale. 1999;25:470–6.PubMedGoogle Scholar
  76. 76.
    Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med. 1990;114:727–8.PubMedGoogle Scholar
  77. 77.
    Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013;4:45.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999;19:870–6.CrossRefPubMedGoogle Scholar
  79. 79.
    Yu CM, Chan JC, Sanderson JE. Chinese herbs and warfarin potentiation by ‘danshen’. J Intern Med. 1997;241:337–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. 2005;12:10–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Pain ManagementCleveland ClinicClevelandUSA

Personalised recommendations